Stock MRK MERCK & CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse
Other stock markets
 04:00:07 2024-05-03 pm EDT 		After market 05:02:00 pm
127.5 USD -0.58% Intraday chart for Merck & Co., Inc. 127.5 -0.00%
May. 02 Merck: encouraging results in gastric cancer CF
May. 01 Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Merck: encouraging results in gastric cancer
CF
Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial
MT
Redburn Atlantic Adjusts Price Target on Merck to $148 From $142
MT
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
BU
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
CI
BioMed X Announces the Start of A New Research Project in Partnership with Merck
CI
Merck Reports Positive Data for Investigational 21-Valent Pneumococcal Vaccine
MT
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
BU
Blackstone beats Concord with $1.6 bln bid for Hipgnosis Songs
RE
Habeck's 'pharma trip' - industry sees structural problems
DP
Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141
MT
Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128
MT
Guggenheim Adjusts Price Target on Merck to $146 From $144
MT
Wells Fargo Adjusts Price Target on Merck & Company to $140 From $135
MT
Deutsche Bank Adjusts Price Target on Merck & Company to $140 From $135
MT
JPMorgan Chase Adjusts Price Target on Merck to $145 From $140
MT
Goldman Sachs Raises Price Target on Merck & Company to $144 From $139
MT
Leerink Partners Raises Price Target on Merck & Company to $136 From $132
MT
Truist Lifts Price Target on Merck to $143 From $142, Keeps Buy Rating
MT
AbbVie raises annual profit forecast on strong Skyrizi sales
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.